Synthetic pharmacotherapy for lupus nephritis

G. Moroni, C. Ponticelli

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Introduction: Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aimed to reduce the potential adverse events without affecting efficacy are reported. Expert opinion: Many synthetic immunosuppressive drugs used in lupus nephritis have a low therapeutic index. Good knowledge of their pharmacologic characteristics, mechanisms of action, and drug-to-drug interactions, coupled with a strategy aimed to increase immunosuppression in the active phases of SLE while reducing the dosage in quiescent periods can reduce the iatrogenic morbidity while maintaining efficacy. Biologic agent may allow to reduce the use or the dosage of synthetic immunosuppressive drugs.

Original languageEnglish
Pages (from-to)175-186
Number of pages12
JournalExpert Opinion on Pharmacotherapy
Volume18
Issue number2
DOIs
Publication statusPublished - Jan 22 2017

Fingerprint

Lupus Nephritis
Drug Therapy
Immunosuppressive Agents
Pharmaceutical Preparations
Systemic Lupus Erythematosus
Morbidity
Expert Testimony
Biological Factors
Drug Interactions
Immunosuppression
Mortality
Therapeutics

Keywords

  • cyclophosphamide
  • glucocorticoids
  • Lupus nephritis
  • purine synthesis inhibitorscalcineurin inhibitors

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Synthetic pharmacotherapy for lupus nephritis. / Moroni, G.; Ponticelli, C.

In: Expert Opinion on Pharmacotherapy, Vol. 18, No. 2, 22.01.2017, p. 175-186.

Research output: Contribution to journalReview article

Moroni, G. ; Ponticelli, C. / Synthetic pharmacotherapy for lupus nephritis. In: Expert Opinion on Pharmacotherapy. 2017 ; Vol. 18, No. 2. pp. 175-186.
@article{0a387f12f0f0427dbd020f0d426472bd,
title = "Synthetic pharmacotherapy for lupus nephritis",
abstract = "Introduction: Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aimed to reduce the potential adverse events without affecting efficacy are reported. Expert opinion: Many synthetic immunosuppressive drugs used in lupus nephritis have a low therapeutic index. Good knowledge of their pharmacologic characteristics, mechanisms of action, and drug-to-drug interactions, coupled with a strategy aimed to increase immunosuppression in the active phases of SLE while reducing the dosage in quiescent periods can reduce the iatrogenic morbidity while maintaining efficacy. Biologic agent may allow to reduce the use or the dosage of synthetic immunosuppressive drugs.",
keywords = "cyclophosphamide, glucocorticoids, Lupus nephritis, purine synthesis inhibitorscalcineurin inhibitors",
author = "G. Moroni and C. Ponticelli",
year = "2017",
month = "1",
day = "22",
doi = "10.1080/14656566.2016.1276563",
language = "English",
volume = "18",
pages = "175--186",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "2",

}

TY - JOUR

T1 - Synthetic pharmacotherapy for lupus nephritis

AU - Moroni, G.

AU - Ponticelli, C.

PY - 2017/1/22

Y1 - 2017/1/22

N2 - Introduction: Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aimed to reduce the potential adverse events without affecting efficacy are reported. Expert opinion: Many synthetic immunosuppressive drugs used in lupus nephritis have a low therapeutic index. Good knowledge of their pharmacologic characteristics, mechanisms of action, and drug-to-drug interactions, coupled with a strategy aimed to increase immunosuppression in the active phases of SLE while reducing the dosage in quiescent periods can reduce the iatrogenic morbidity while maintaining efficacy. Biologic agent may allow to reduce the use or the dosage of synthetic immunosuppressive drugs.

AB - Introduction: Lupus nephritis is a frequent complication and a major cause of morbidity and mortality in patients with systemic lupus erythematosus (SLE). Area covered: The main characteristics and mechanisms of action of the synthetic drugs more frequently used in lupus nephritis are described. Possible strategies aimed to reduce the potential adverse events without affecting efficacy are reported. Expert opinion: Many synthetic immunosuppressive drugs used in lupus nephritis have a low therapeutic index. Good knowledge of their pharmacologic characteristics, mechanisms of action, and drug-to-drug interactions, coupled with a strategy aimed to increase immunosuppression in the active phases of SLE while reducing the dosage in quiescent periods can reduce the iatrogenic morbidity while maintaining efficacy. Biologic agent may allow to reduce the use or the dosage of synthetic immunosuppressive drugs.

KW - cyclophosphamide

KW - glucocorticoids

KW - Lupus nephritis

KW - purine synthesis inhibitorscalcineurin inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85011675448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011675448&partnerID=8YFLogxK

U2 - 10.1080/14656566.2016.1276563

DO - 10.1080/14656566.2016.1276563

M3 - Review article

VL - 18

SP - 175

EP - 186

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -